Integral Health Asset Management, LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Integral Health Asset Management, LLC reported 84 stock positions worth $2.0 billion. Its top holding was Insmed (INSM) at 11.0% of the portfolio, followed by Revolution Medicines (RVMD, 4.8%) and Vera Therapeutics (VERA, 4.6%). Compared with Q3 2025, it opened 23 new positions, sold out of 11, added to 34 and reduced 19. The biggest buy was Revolution Medicines (RVMD, shares +200%) and the biggest sale Insmed (INSM, shares −22%).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001773206
- Portfolio Value
- $2.0B (Q4 2025)
- SEC Filing
- 0001172661-26-000915 ↗ filed Feb 17, 2026
Holdings Value
Holdings 84 stocks · $2.0B
| INSM Insmed Inc. | 11.03% | 1,250,000 | $217.6M | Reduce -21.9% |
| RVMD Revolution Medicines Inc. | 4.84% | 1,200,000 | $95.6M | Add +200.0% |
| VERA Vera Therapeutics Inc. | 4.62% | 1,800,000 | $91.2M | Add +5.9% |
| CYTK Cytokinetics Inc. | 4.51% | 1,400,000 | $89.0M | No change |
| REGN Regeneron Pharmaceuticals | 4.11% | 105,000 | $81.0M | Add +110.0% |
| MDT Medtronic PLC | 3.29% | 675,000 | $64.8M | Add +350.0% |
| ISRG Intuitive Surgical Inc. | 3.16% | 110,000 | $62.3M | Add +340.0% |
| RYTM Rhythm Pharmaceuticals Inc. | 2.58% | 475,000 | $50.8M | Add +115.9% |
| ALHC Alignment Healthcare Inc. | 2.20% | 2,200,000 | $43.5M | Add +37.5% |
| CAH Cardinal Health Inc. | 2.08% | 200,000 | $41.1M | Add +53.9% |
| CVS CVS Health Corp. | 2.01% | 500,000 | $39.7M | Add +150.0% |
| EWTX Edgewise Therapeutics Inc. | 1.89% | 1,500,000 | $37.2M | No change |
| GKOS Glaukos Corp. | 1.86% | 325,000 | $36.7M | Add +225.0% |
| NVS Novartis AG-Sponsored ADR | 1.75% | 250,000 | $34.5M | Add +25.0% |
| DXCM Dexcom Inc. | 1.68% | 500,000 | $33.2M | New |
| AZN Astrazeneca PLC-Spons ADR | 1.63% | 350,000 | $32.2M | Add +16.7% |
| TEVA Teva Pharmaceutical-SP ADR | 1.58% | 1,000,000 | $31.2M | New |
| PEN Penumbra Inc. | 1.58% | 100,000 | $31.1M | Add +100.0% |
| TFX Teleflex Inc. | 1.55% | 250,000 | $30.5M | New |
| BTSG Brightspring Health Services | 1.42% | 750,000 | $28.1M | Reduce -34.8% |
| EW Edwards Lifesciences Corp. | 1.40% | 325,000 | $27.7M | Add +62.5% |
| MLYS Mineralys Therapeutics Inc. | 1.38% | 750,000 | $27.2M | Reduce -50.0% |
| CNC Centene Corp. | 1.36% | 650,000 | $26.7M | Add +62.5% |
| COO The Cooper Cos Inc. | 1.35% | 325,000 | $26.6M | Add +242.1% |
| MRK Merck & Co. Inc. | 1.33% | 250,000 | $26.3M | New |
| ALNY Alnylam Pharmaceuticals Inc. | 1.21% | 60,000 | $23.9M | No change |
| IRTC Irhythm Holdings Inc. | 1.17% | 130,000 | $23.1M | Add +100.0% |
| QURE Uniqure NV | 1.09% | 900,000 | $21.5M | Add +50.0% |
| LLY Eli Lilly & Co. | 1.09% | 20,000 | $21.5M | No change |
| BSX Boston Scientific Corp. | 1.09% | 225,000 | $21.5M | Reduce -25.0% |
| NBIX Neurocrine Biosciences Inc. | 1.08% | 150,000 | $21.3M | No change |
| LFST Lifestance Health Group Inc. | 1.07% | 3,000,000 | $21.1M | Add +100.0% |
| ELV Elevance Health Inc. | 1.07% | 60,000 | $21.0M | Add +20.0% |
| UPB Upstream Bio Inc. | 1.03% | 750,000 | $20.4M | Add +30.4% |
| THC Tenet Healthcare Corp. | 1.01% | 100,000 | $19.9M | Reduce -66.7% |
| ASND Ascendis Pharma A/S | 0.97% | 90,000 | $19.2M | Add +50.0% |
| ROIV Roivant Sciences Ltd. | 0.93% | 850,000 | $18.4M | Add +13.3% |
| DOCS Doximity Inc. Class A | 0.90% | 400,000 | $17.7M | Add +122.2% |
| BIIB Biogen Inc. | 0.89% | 100,000 | $17.6M | New |
| RGNX Regenxbio Inc. | 0.88% | 1,200,000 | $17.3M | Add +9.1% |
| TERN Terns Pharmaceuticals Inc. | 0.87% | 425,000 | $17.2M | Reduce -55.3% |
| BHVN Biohaven Ltd. | 0.86% | 1,500,000 | $16.9M | Add +130.8% |
| UNH Unitedhealth Group Inc. | 0.84% | 50,000 | $16.5M | New |
| TARS Tarsus Pharmaceuticals Inc. | 0.83% | 200,000 | $16.4M | Reduce -20.0% |
| FMS Fresenius Medical Care-ADR | 0.78% | 650,000 | $15.5M | Add +44.4% |
| BEAM Beam Therapeutics Inc. | 0.77% | 550,000 | $15.2M | Add +37.5% |
| SLNO Soleno Therapeutics Inc. | 0.76% | 325,000 | $15.0M | New |
| RDNT Radnet Inc. | 0.72% | 200,000 | $14.3M | Reduce -33.3% |
| SRRK Scholar Rock Holding Corp. | 0.67% | 300,000 | $13.2M | Add +200.0% |
| ACLX Arcellx Inc. | 0.66% | 200,000 | $13.0M | Add +33.3% |
| DGX Quest Diagnostics Inc. | 0.66% | 75,000 | $13.0M | Reduce -11.8% |
| SANA Sana Biotechnology Inc. | 0.62% | 3,000,000 | $12.2M | Add +50.0% |
| TARA Protara Therapeutic Inc. | 0.61% | 2,250,000 | $12.0M | Add +60.7% |
| PRAX Praxis Precision Medicines I | 0.60% | 40,000 | $11.8M | New |
| DNTH Dianthus Therapeutics Inc. | 0.57% | 275,000 | $11.3M | Add +83.3% |
| NVST Envista Holdings Corp. | 0.55% | 500,000 | $10.9M | Reduce -9.1% |
| EHC Encompass Health Corp. | 0.54% | 100,000 | $10.6M | Reduce -50.0% |
| ORIC Oric Pharmaceuticals Inc. | 0.50% | 1,200,000 | $9.8M | Add +33.3% |
| CRL Charles River Laboratories | 0.45% | 45,000 | $9.0M | Reduce -25.0% |
| CELC Celcuity Inc. | 0.40% | 80,000 | $8.0M | New |
| INSP Inspire Medical Systems Inc. | 0.35% | 75,000 | $6.9M | Reduce -37.5% |
| ANRO Alto Neuroscience Inc. | 0.34% | 375,000 | $6.7M | Reduce -6.3% |
| LNTH Lantheus Holdings Inc. | 0.34% | 100,000 | $6.7M | New |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.34% | 100,000 | $6.6M | Reduce -55.6% |
| BRKR Bruker Corp. | 0.30% | 125,000 | $5.9M | New |
| NRIX Nurix Therapeutics Inc. | 0.29% | 300,000 | $5.7M | Reduce -14.3% |
| ELAN Elanco Animal Health Inc. | 0.29% | 250,000 | $5.7M | Reduce -68.8% |
| APLS Apellis Pharmaceuticals Inc. | 0.25% | 200,000 | $5.0M | Reduce -20.0% |
| RZLT Rezolute Inc. | 0.24% | 2,000,000 | $4.7M | No change |
| MIND MEDICINE MINDMED INC | 0.24% | 350,000 | $4.7M | New |
| SNDX Syndax Pharmaceuticals Inc. | 0.21% | 200,000 | $4.2M | New |
| MAZE Maze Therapeutics Inc. | 0.21% | 100,000 | $4.1M | New |
| EYPT Eyepoint Inc. | 0.19% | 200,000 | $3.7M | New |
| IKT Inhibikase Therapeutics Inc. | 0.18% | 1,750,000 | $3.6M | New |
| VKTX Viking Therapeutics Inc. | 0.18% | 100,000 | $3.5M | New |
| GPCR Structure Therapeutics Inc. | 0.18% | 50,000 | $3.5M | New |
| SGHT Sight Sciences Inc. | 0.17% | 425,000 | $3.4M | New |
| GOSS Gossamer Bio Inc. | 0.16% | 1,000,000 | $3.1M | New |
| OSCR Oscar Health Inc. Class A | 0.15% | 200,000 | $2.9M | Reduce -63.6% |
| LBRX LB Pharmaceuticals Inc. | 0.11% | 100,000 | $2.2M | No change |
| EVMN Evommune Inc. | 0.11% | 125,000 | $2.1M | New |
| TENX Tenax Therapeutics Inc. | 0.10% | 167,000 | $2.0M | No change |
| TNGX Tango Therapeutics Inc. | 0.09% | 200,000 | $1.8M | New |
| BCRX Biocryst Pharmaceuticals Inc. | 0.08% | 200,000 | $1.6M | New |
Options reported separately and not counted above: CYTK calls ($31.8M), MLYS calls ($9.1M).
Portfolio Sells Q3 2025 → Q4 2025
| INSM Insmed Inc. | Reduce -21.9% | 11.03% | −5.77 |
| THC Tenet Healthcare Corp. | Reduce -66.7% | 1.01% | −3.43 |
| MLYS Mineralys Therapeutics Inc. | Reduce -50.0% | 1.38% | −2.77 |
| EHC Encompass Health Corp. | Reduce -50.0% | 0.54% | −1.31 |
| BTSG Brightspring Health Services | Reduce -34.8% | 1.42% | −1.05 |
| BSX Boston Scientific Corp. | Reduce -25.0% | 1.09% | −1.05 |
| RDNT Radnet Inc. | Reduce -33.3% | 0.72% | −0.94 |
| PFE Pfizer Inc. | Sold out | 0.00% | −0.93 |
| ELAN Elanco Animal Health Inc. | Reduce -68.8% | 0.29% | −0.89 |
| MCK McKesson Corp. | Sold out | 0.00% | −0.84 |
| A Agilent Technologies Inc. | Sold out | 0.00% | −0.84 |
| EXAS Exact Sciences Corp. | Sold out | 0.00% | −0.80 |
| DYN Dyne Therapeutics Inc. | Sold out | 0.00% | −0.74 |
| IQV Iqvia Holdings Inc. | Sold out | 0.00% | −0.62 |
| OSCR Oscar Health Inc. Class A | Reduce -63.6% | 0.15% | −0.61 |
| ACHC Acadia Healthcare Co. Inc. | Sold out | 0.00% | −0.54 |
| DGX Quest Diagnostics Inc. | Reduce -11.8% | 0.66% | −0.52 |
| HOLX Hologic Inc. | Sold out | 0.00% | −0.49 |
| JNJ Johnson & Johnson | Sold out | 0.00% | −0.41 |
| PHVS Pharvaris NV | Sold out | 0.00% | −0.36 |
| INSP Inspire Medical Systems Inc. | Reduce -37.5% | 0.35% | −0.30 |
| ESPR Esperion Therapeutics Inc. | Sold out | 0.00% | −0.29 |
| NVST Envista Holdings Corp. | Reduce -9.1% | 0.55% | −0.27 |
| TARS Tarsus Pharmaceuticals Inc. | Reduce -20.0% | 0.83% | −0.25 |
| CRL Charles River Laboratories | Reduce -25.0% | 0.45% | −0.23 |
| ARWR Arrowhead Pharmaceuticals Inc. | Reduce -55.6% | 0.34% | −0.23 |
| APLS Apellis Pharmaceuticals Inc. | Reduce -20.0% | 0.25% | −0.16 |
| NRIX Nurix Therapeutics Inc. | Reduce -14.3% | 0.29% | +0.05 |
| ANRO Alto Neuroscience Inc. | Reduce -6.3% | 0.34% | +0.22 |
| TERN Terns Pharmaceuticals Inc. | Reduce -55.3% | 0.87% | +0.35 |
Portfolio Buys Q3 2025 → Q4 2025
| RVMD Revolution Medicines Inc. | Add +200.0% | 4.84% | +3.48 |
| ISRG Intuitive Surgical Inc. | Add +340.0% | 3.16% | +2.34 |
| MDT Medtronic PLC | Add +350.0% | 3.29% | +2.24 |
| REGN Regeneron Pharmaceuticals | Add +110.0% | 4.11% | +2.06 |
| DXCM Dexcom Inc. | New | 1.68% | +1.68 |
| TEVA Teva Pharmaceutical-SP ADR | New | 1.58% | +1.58 |
| TFX Teleflex Inc. | New | 1.55% | +1.55 |
| MRK Merck & Co. Inc. | New | 1.33% | +1.33 |
| GKOS Glaukos Corp. | Add +225.0% | 1.86% | +1.27 |
| VERA Vera Therapeutics Inc. | Add +5.9% | 4.62% | +1.02 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +115.9% | 2.58% | +0.96 |
| CVS CVS Health Corp. | Add +150.0% | 2.01% | +0.91 |
| BIIB Biogen Inc. | New | 0.89% | +0.89 |
| COO The Cooper Cos Inc. | Add +242.1% | 1.35% | +0.88 |
| UNH Unitedhealth Group Inc. | New | 0.84% | +0.84 |
| SLNO Soleno Therapeutics Inc. | New | 0.76% | +0.76 |
| PEN Penumbra Inc. | Add +100.0% | 1.58% | +0.65 |
| PRAX Praxis Precision Medicines I | New | 0.60% | +0.60 |
| CAH Cardinal Health Inc. | Add +53.9% | 2.08% | +0.60 |
| LFST Lifestance Health Group Inc. | Add +100.0% | 1.07% | +0.47 |
| CELC Celcuity Inc. | New | 0.40% | +0.40 |
| SRRK Scholar Rock Holding Corp. | Add +200.0% | 0.67% | +0.40 |
| IRTC Irhythm Holdings Inc. | Add +100.0% | 1.17% | +0.35 |
| LNTH Lantheus Holdings Inc. | New | 0.34% | +0.34 |
| CNC Centene Corp. | Add +62.5% | 1.36% | +0.32 |
| BRKR Bruker Corp. | New | 0.30% | +0.30 |
| EW Edwards Lifesciences Corp. | Add +62.5% | 1.40% | +0.27 |
| UPB Upstream Bio Inc. | Add +30.4% | 1.03% | +0.24 |
| MIND MEDICINE MINDMED INC | New | 0.24% | +0.24 |
| SNDX Syndax Pharmaceuticals Inc. | New | 0.21% | +0.21 |
| MAZE Maze Therapeutics Inc. | New | 0.21% | +0.21 |
| EYPT Eyepoint Inc. | New | 0.19% | +0.19 |
| IKT Inhibikase Therapeutics Inc. | New | 0.18% | +0.18 |
| VKTX Viking Therapeutics Inc. | New | 0.18% | +0.18 |
| GPCR Structure Therapeutics Inc. | New | 0.18% | +0.18 |
| SGHT Sight Sciences Inc. | New | 0.17% | +0.17 |
| ALHC Alignment Healthcare Inc. | Add +37.5% | 2.20% | +0.17 |
| TARA Protara Therapeutic Inc. | Add +60.7% | 0.61% | +0.16 |
| GOSS Gossamer Bio Inc. | New | 0.16% | +0.16 |
| BHVN Biohaven Ltd. | Add +130.8% | 0.86% | +0.15 |
| DNTH Dianthus Therapeutics Inc. | Add +83.3% | 0.57% | +0.14 |
| EVMN Evommune Inc. | New | 0.11% | +0.11 |
| ROIV Roivant Sciences Ltd. | Add +13.3% | 0.93% | +0.11 |
| ASND Ascendis Pharma A/S | Add +50.0% | 0.97% | +0.10 |
| RGNX Regenxbio Inc. | Add +9.1% | 0.88% | +0.10 |
| SANA Sana Biotechnology Inc. | Add +50.0% | 0.62% | +0.10 |
| TNGX Tango Therapeutics Inc. | New | 0.09% | +0.09 |
| BCRX Biocryst Pharmaceuticals Inc. | New | 0.08% | +0.08 |
| BEAM Beam Therapeutics Inc. | Add +37.5% | 0.77% | +0.07 |
| AZN Astrazeneca PLC-Spons ADR | Add +16.7% | 1.63% | −0.05 |
Options Activity Q3 2025 → Q4 2025
| CYTK Cytokinetics Inc. | call | Reduce -33.3% | 500,000 | $31.8M |
| NAMS Newamsterdam Pharma Co. NV | put | Sold out | 1,000,000 | $28.4Mbefore exit |
| NVO Novo-Nordisk A/S-Spons ADR | put | Sold out | 400,000 | $22.2Mbefore exit |
| INSM Insmed Inc. | put | Sold out | 100,000 | $14.4Mbefore exit |
| MLYS Mineralys Therapeutics Inc. | call | New | 250,000 | $9.1M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 89 | $2.4B | RVMD, INSM, CYTK, CVS, EWTX |
| Q1 2026 | 86 | $1.9B | INSM, RVMD, CYTK, REGN, VERA |
| Q4 2025 | 84 | $2.0B | INSM, RVMD, VERA, CYTK, REGN |
| Q3 2025 | 72 | $1.4B | INSM, CYTK, THC, MLYS, VERA |
| Q2 2025 | 70 | $1.1B | INSM, BSX, THC, EHC, MLYS |
| Q1 2025 | 76 | $902.7M | INSM, BSX, CYTK, THC, MLYS |
| Q4 2024 | 81 | $1.1B | INSM, THC, BSX, VERA, CYTK |
| Q3 2024 | 63 | $849.4M | INSM, THC, BSX, CYTK, LBPH |
| Q2 2024 | 69 | $1.0B | INSM, THC, CYTK, BSX, ELV |
| Q1 2024 | 76 | $1.0B | THC, BSX, VKTX, INSM, CYTK |